Literature DB >> 25042465

Dynamics of HCV RNA levels during acute hepatitis C virus infection.

Behzad Hajarizadeh1, Jason Grebely, Tanya Applegate, Gail V Matthews, Janaki Amin, Kathy Petoumenos, Margaret Hellard, William Rawlinson, Andrew Lloyd, John Kaldor, Gregory J Dore.   

Abstract

Understanding viral dynamics during acute hepatitis C virus (HCV) infection can provide important insights into immunopathogenesis and guide early treatment. The aim of this study was to investigate the dynamics of HCV RNA and alanine transaminase (ALT) levels during recent HCV infection in the Australian Trial in Acute Hepatitis C (ATAHC). ATAHC was a prospective study of the natural history of recently acquired HCV infection. Longitudinal HCV RNA and ALT levels were compared among individuals with persistent infection and spontaneous clearance. Among those with HCV persistence (n = 104) and HCV clearance (n = 30), median HCV RNA (5.2 vs. 4.1 log IU/ml, respectively) and ALT levels (779 vs. 1,765 IU/L, respectively) were high during month two following infection, and then declined during months three and four in both groups. Among those with HCV persistence, median HCV RNA was 2.9 log IU/ml during months four, increased to 5.5 log IU/ml during month five, and remained subsequently relatively stable. Among those with HCV clearance, median HCV RNA was undetectable by month five. Median HCV RNA levels were comparable between individuals with HCV persistence and HCV clearance during month three following infection (3.2 vs. 3.5 log IU/ml, respectively; P = 0.935), but markedly different during month five (5.5 vs. 1.0 log IU/ml, respectively; P < 0.001). In conclusion, dynamics of HCV RNA levels in those with HCV clearance and HCV persistence diverged between months three and five following infection, with the latter time-point being potentially useful for commencing early treatment.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  alanine transaminase; chronic; persistent infection; spontaneous clearance; viral load

Mesh:

Substances:

Year:  2014        PMID: 25042465      PMCID: PMC4276420          DOI: 10.1002/jmv.24010

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  29 in total

1.  Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection.

Authors:  Judith H Aberle; Elisabeth Formann; Petra Steindl-Munda; Lukas Weseslindtner; Calin Gurguta; Gabriela Perstinger; Evelyn Grilnberger; Hermann Laferl; Hans P Dienes; Theresia Popow-Kraupp; Peter Ferenci; Heidemarie Holzmann
Journal:  J Clin Virol       Date:  2006-02-17       Impact factor: 3.168

Review 2.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

3.  Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia.

Authors:  Mingdong Zhang; Philip S Rosenberg; Deborah L Brown; Liliana Preiss; Barbara A Konkle; M Elaine Eyster; James J Goedert
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

4.  Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.

Authors:  C Micha Nübling; Gabriele Unger; Michael Chudy; Steven Raia; Johannes Löwer
Journal:  Transfusion       Date:  2002-08       Impact factor: 3.157

5.  Dynamics of viremia in early hepatitis C virus infection.

Authors:  Simone A Glynn; David J Wright; Steven H Kleinman; Dale Hirschkorn; Yongling Tu; Charles Heldebrant; Richard Smith; Cristina Giachetti; James Gallarda; Michael P Busch
Journal:  Transfusion       Date:  2005-06       Impact factor: 3.157

6.  Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.

Authors:  Dimitri Lavillette; Yoann Morice; Georgios Germanidis; Peggy Donot; Alexandre Soulier; Emanuil Pagkalos; Georgios Sakellariou; Liliane Intrator; Birke Bartosch; Jean-Michel Pawlotsky; François-Loïc Cosset
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

8.  Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China.

Authors:  Rebecca-J Garten; Sheng-Han Lai; Jin-Bing Zhang; Wei Liu; Jie Chen; Xiao-Fang Yu
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

9.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196

10.  Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C.

Authors:  J M Barrera; M Bruguera; M G Ercilla; C Gil; R Celis; M P Gil; M del Valle Onorato; J Rodés; A Ordinas
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

View more
  11 in total

1.  Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Authors:  Behzad Hajarizadeh; Bart Grady; Kimberly Page; Arthur Y Kim; Barbara H McGovern; Andrea L Cox; Thomas M Rice; Rachel Sacks-Davis; Julie Bruneau; Meghan Morris; Janaki Amin; Janke Schinkel; Tanya Applegate; Lisa Maher; Margaret Hellard; Andrew R Lloyd; Maria Prins; Ronald B Geskus; Gregory J Dore; Jason Grebely
Journal:  J Clin Virol       Date:  2014-09-08       Impact factor: 3.168

2.  Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Authors:  B Hajarizadeh; B Grady; K Page; A Y Kim; B H McGovern; A L Cox; T M Rice; R Sacks-Davis; J Bruneau; M Morris; J Amin; J Schinkel; T Applegate; L Maher; M Hellard; A R Lloyd; M Prins; R B Geskus; G J Dore; J Grebely
Journal:  J Viral Hepat       Date:  2015-01-08       Impact factor: 3.728

3.  Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Authors:  Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

Review 4.  Contextualizing Canada's hepatitis C virus epidemic.

Authors:  Mel Krajden; Darrel Cook; Naveed Z Janjua
Journal:  Can Liver J       Date:  2018-12-25

5.  Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.

Authors:  J Morgan Freiman; Jianing Wang; Philippa J Easterbrook; C Robert Horsburgh; Francesco Marinucci; Laura F White; George Kamkamidze; Mel Krajden; Anne Loarec; Richard Njouom; Kihn V Nguyen; Gamal Shiha; Reham Soliman; Sunil S Solomon; Tengiz Tsertsvadze; Claudia M Denkinger; Benjamin Linas
Journal:  J Hepatol       Date:  2019-02-21       Impact factor: 30.083

6.  Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.

Authors:  Behzad Hajarizadeh; Bart Grady; Kimberly Page; Arthur Y Kim; Barbara H McGovern; Andrea L Cox; Thomas M Rice; Rachel Sacks-Davis; Julie Bruneau; Meghan Morris; Janaki Amin; Janke Schinkel; Tanya Applegate; Lisa Maher; Margaret Hellard; Andrew R Lloyd; Maria Prins; Gregory J Dore; Jason Grebely
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

7.  Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.

Authors:  Bastian Neesgaard; Morten Ruhwald; Henrik B Krarup; Nina Weis
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

8.  Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships.

Authors:  Judith A Hahn; Damien C Tully; Jennifer L Evans; Meghan D Morris; Alya Briceno; David J Bean; Todd M Allen; Kimberly Page
Journal:  Open Forum Infect Dis       Date:  2019-04-25       Impact factor: 3.835

9.  Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

Authors:  Viviane D Lima; Ignacio Rozada; Jason Grebely; Mark Hull; Lillian Lourenco; Bohdan Nosyk; Mel Krajden; Eric Yoshida; Evan Wood; Julio S G Montaner
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

10.  The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.

Authors:  Tengiz Tsertsvadze; Lali Sharvadze; Nikoloz Chkhartishvili; Lela Dzigua; Marine Karchava; Lana Gatserelia; Akaki Abutidze; Kenrad E Nelson
Journal:  Virol J       Date:  2016-02-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.